For THERF that was a 100% increase in share price.
Post# of 148301
With the current blaise attitude toward our stock I think it will take increasing script numbers and revenue for our share price to start reflecting it's actual worth. By September 2020 I would expect $5.00 per share. What will really drive this stock price is full Phase 2 mTNBC trial results and interim mono results.
Very long term, on any metastatic cancer approval I would expect $75-$80 a share.